In addition, ATP-binding cassette transporters in aggressive lymphoma can modulate exosome release, which leads to exosome-mediated shielding of target cells as a critical determinant of tumor cell susceptibility to antibody therapy [42]. This evidence concerns the gene ABCA4 and lymphoma.